Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $0
- PE ratio
- —
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 2,000
- Avg volume
- 2,026
- Day's range
- $0.22 – $0.24
- Shares out
- —
- Stochastic %K
- 47%
- Beta
- —
- Analysts
- Strong Buy
- Price target
- —
Company profile
Onco-Innovations Limited, a pre-clinical stage biotechnology company, develops drug candidates for cancer treatments in Canada. The company's lead product candidate is ONC010, an inhibitor of the DNA repair enzyme polynucleotide kinase 3'-phosphatase (PNKP) in a nanoparticle formulation based on drug delivery technology. It also develops SynoGraph technology, an artificial intelligence-powered tool to accelerate prec...
Show more
Onco-Innovations Limited, a pre-clinical stage biotechnology company, develops drug candidates for cancer treatments in Canada. The company's lead product candidate is ONC010, an inhibitor of the DNA repair enzyme polynucleotide kinase 3'-phosphatase (PNKP) in a nanoparticle formulation based on drug delivery technology. It also develops SynoGraph technology, an artificial intelligence-powered tool to accelerate precision oncology breakthroughs and de-risk drug development. In addition, the company engages in research and development activities. It has collaborations with Dalton Pharma Services, the University of Alberta and Cross Cancer Institute, Nucro-Technics Inc., and Avance Clinical Pty Ltd. Onco-Innovations Limited is headquartered in Calgary, Canada.
- Industry
- Biotechnology
- Sector
- Healthcare
- Website
- https://oncoinnovations.com
- Address
- 1122 – 4th Street SW, Suite 1000, Calgary, Canada
Latest news
No headlines yet.
